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Heart failure (HF) is one of the leading causes for mortality and
morbidity worldwide. Despite advantages in themanagement and
treatment of this syndrome, nowadays, it is estimated that 50%
of HF patients die within 5 years from diagnosis (McMurray
et al., 2012). Thus, a better understanding of the molecular
mechanisms underlying structural, functional, neuro-hormonal,
and metabolic alterations of the failing heart is necessary for
the identification of new therapeutic targets and strategies. The
adrenergic system is crucial for cardiac function, and even
more critical in diseased states characterized by elevated sympa-
thetic nervous system (SNS) hyperactivity (Lymperopoulos et al.,
2013). SNS hyperactivity is a salient characteristic of chronic HF
and causes cardiac up-regulation of G protein-coupled receptor
kinase 2 (GRK2), which in turn induces beta-adrenergic receptor
dysregulation in the heart (Rengo et al., 2009, 2012).
The present Research Topic aims to present some of the more
relevant and recent acquisitions on the molecular abnormalities
of the adrenergic system occurring in HF. Dr. Lymperopoulos
has reported the molecular mechanisms of regulation of SNS in
HF patho-physiology, discussing their therapeutic implications
for the failing heart (Lymperopoulos, 2013). The importance of
SNS hyperactivity as a main therapeutic target in HF, represents
the rationale for the use of beta-blockers, as discussed by Drs.
Barrese and Taglialatela. These authors also reported the molec-
ular bases explaining the differences in response to beta-blocker
therapy among HF patients (Barrese and Taglialatela, 2013).
Dr. Ferrara and collaborators showed the molecular similarities
between physiological aging and HF. Both these conditions are
characterized by SNS hyperactivity and cardiac beta-adrenergic
receptor signaling dysfunction, and this may help to explain
why HF is more frequent and its manifestation more severe
in the elderly patients (Ferrara et al., 2014). The intercon-
nections between adrenergic system and cardiac metabolism,
oxidative stress and nitric oxide signaling have also been dis-
cussed in this Research Topic. It is known from several years
that the adrenergic system has a profound effect on the reg-
ulation of cardiac metabolism. In this regard, Ciccarelli et al.
reported the most updated discoveries in the molecular mech-
anisms involved in the interactions between adrenergic system
hyperactivity and metabolic abnormalities, such as insulin resis-
tance and altered glucose metabolism (Ciccarelli et al., 2013).
The effects of beta-adrenoceptors on Reactive Oxygen Species
generation are described by Corbi et al.; these authors reported
also a fascinating hypothesis of the involvement of sirtuins
on beta-adrenergic receptors signaling with a potential role in
HF pathophysiology (Corbi et al., 2013). Dr. Conti and col-
laborators reported the mechanisms of the crosstalk between
nitric oxide and beta-adrenergic receptor system, in particu-
lar in the control of endothelial function and vascular tone
(Conti et al., 2013).
Evidences accumulated over the past 20 years support the
pathogenic key role of cardiac GRK2 levels/activity in determin-
ing HF-related beta-adrenergic receptor dysfunction and cardiac
inotropic reserve reduction. All these data indicate GRK2 inhi-
bition, via gene therapy, as a new HF therapeutic approach that
has been shown to be compatible and, in some models, also syn-
ergistic to beta-blockers. Cannavo et al. provide a contemporary
update of this field by describing the therapeutic potentialities
of this approach and its beneficial effects not only on beta-
adrenergic receptor signaling, but also on cardiac metabolism,
apoptosis, and mitochondrial dysfunction (Cannavo et al., 2013).
De Lucia and collaborators extended the therapeutic potentiali-
ties of GRK2 inhibition to the adrenal glands and to the control
of HF-related SNS outflow (de Lucia et al., 2014). Since its first
demonstration by Lymperopoulos et al. (2007), GRK2 appeared
to be critical in the regulation of adrenal alfa2 adrenergic receptor
function, extending also to other organs the therapeutic bene-
fits of GRK2 inhibition in HF. Finally, Dr. Leosco in his review
explained the molecular mechanisms involved in the beneficial
effects of exercise training in curbing SNS hyperactivity and beta-
adrenergic receptor dysfunction observed in HF. A crucial role
seems to be played by the ability of physical activity to reduce
GRK2 levels both in the heart and in the adrenal medulla, with
relevant effects on cardiovascular function (Leosco et al., 2013).
The overall Research Topic indicates that the great advances
achieved in the last decades in understanding the molecular alter-
ations involved in the pathophysiology of HF are opening new
opportunities for the treatment of this syndrome and, potentially,
their future application to the clinical practice might result to
further improvements of patient care. Moreover, the interesting
new findings, discussed herein, will hopefully stimulate further
research on these arguments.
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